References
- Galbiatti AL , da Silva LM, Ruiz-Cintra MT et al. Association between 11 genetic polymorphisms in folate-metabolising genes and head and neck cancer risk. Eur. J. Cancer48(10) , 1525–1531 (2012).
- Delgado-Plasencia L , Medina-AranaV, Bravo-GutiérrezA et al. Impact of the MTHFR C677T polymorphism on colorectal cancer in a population with low genetic variability. Int. J. Colorectal Dis. doi:10.1007/s00384-013-1644-6 (2013) (Epub ahead of print).
- Frosst P , BlomHJ, MilosR et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat. Genet. 10(1) , 111–113 (1995).
- Danenberg PV , MalliH, SwensonS. Thymidylate synthase inhibitors. Semin. Oncol.26(6) , 621–631 (1999).
- Ciccolini J , CuqP, EvrardA et al. Combination of thymidine phosphorylase gene transfer and deoxyinosine treatment greatly enhances 5-fluorouracil antitumor activity in vitro and in vivo. Mol. Cancer Ther. 1(2) , 133–139 (2001).
- Etienne-Grimaldi MC , MilanoG, Maindrault-GoebelF et al. Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients. Br. J. Clin. Pharmacol. 69(1) , 58–66 (2010).
- Andre F , CiccoliniJ, SpanoJP et al. Personalized medicine in oncology: where have we come from and where are we going? Pharmacogenomics 14(8) , 931–939 (2013).
References
- Andre F , CiccoliniJ, SpanoJP et al. Personalized medicine in oncology: where have we come from and where are we going? Pharmacogenomics 14(8) , 931–939 (2013).
- Tamandl D , KlingerM, EipeldauerS et al. Sinusoidal obstruction syndrome impairs long-term outcome of colorectal liver metastases treated with resection after neoadjuvant chemotherapy. Ann. Surg. Oncol. 18(2) , 421–430 (2011).
- Vauthey JN , PawlikTM, RiberoD et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J. Clin. Oncol. 24(13) , 2065–2072 (2006).
- Robinson SM , MannJ, ManasDM, MannDA, WhiteSA. An experimental study to identify the potential role of pharmacogenomics in determining the occurrence of oxaliplatin-induced liver injury. HPB (Oxford) doi:10.1111/hpb.12010 (2012) (Epub ahead of print).
- Holzer AK , ManorekGH, HowellSB. Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin. Mol. Pharmacol.70(4) , 1390–1394 (2006).
- Blair BG , LarsonCA, AdamsPL, AbadaPB, SafaeiR, HowellSB. Regulation of copper transporter 2 expression by copper and cisplatin in human ovarian carcinoma cells. Mol. Pharmacol.7(6) , 912–921 (2010).